34c0a7a8-8ce8-4a2a-9bce-939eb2f6f1d9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- DNA_REPAIR+0.400
- ANGIOGENESIS+0.300
- FATTY_ACID_METABOLISM+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- MTORC1_SIGNALING+0.300
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- APICAL_SURFACE-0.400
- HEDGEHOG_SIGNALING-0.400
- KRAS_SIGNALING_DN-0.400
- TGF_BETA_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- IL2_STAT5_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- KRAS_SIGNALING_UP-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0f35c851-1cb8-4f75-a661-eae9111b7362 | — | — | 0.860 |
| 2 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.838 |
| 3 | C3N-00580 | — | cohortA1 | 0.838 |
| 4 | TCGA-A8-A092-01A-11R-A00Z-07 | — | B | 0.830 |
| 5 | SRR27320678 | — | — | 0.827 |
| 6 | MNG606 | — | — | 0.822 |
| 7 | SRR17866823 | — | — | 0.812 |
| 8 | fac69f81-0d8c-40a0-8263-b54d5f06d7b3 | — | — | 0.810 |
| 9 | 1cbc5c3a-eb0f-4492-9171-5e0a61923c33 | — | — | 0.808 |
| 10 | MNG241 | — | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |